TOKYO -- A Japanese startup is poised to become the first in the world to seek government approval for a therapy derived from human induced pluripotent stem (iPS) cells, Nikkei has learned, with a less invasive alternative for treating heart disease.
Pharmaceuticals
Japan startup to seek approval for iPS cell therapy in global first
Cuorips to submit application as early as June for heart disease treatment
The cardiac tissue sheet developed by Cuorips can be grafted onto the hearts of patients suffering from coronary artery disease. (Cuorips)
Read Next
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Pharmaceuticals
